The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients

HIV Clinical Trials
Maaike KrikkeJoop E Arends

Abstract

Objective Lipid management is one of the cornerstones of cardiovascular risk reduction. Treatment of HIV infection with protease inhibitors (PIs) may cause dyslipidaemia, whilst the integrase inhibitor raltegravir (RAL) has a relatively favorable effect on plasma lipids. We examined the effect of switching from PIs to RAL on endothelial function, and its effect on immunological and inflammatory parameters. Methods We performed a 16-week open-label prospective crossover study: 8 weeks intervention (switch PIs to RAL) and 8 weeks control (unchanged cART regimen). Flow-mediated dilatation (FMD), inflammatory plasma, and cellular markers of immune activation were measured at weeks 0, 8, and 16. Results Study participants (n = 22) with a median age of 50 years (IQR 42-60) and known HIV infection of 6.5 years (IQR 5.0-17.3) were on stable cART with undetectable HIV viral loads. After 8 weeks of RAL therapy, a reduction in FMD of -0.81% was seen, compared to +0.54% control (pairwise, p = 0.051), while fasting total cholesterol (-17% versus +10%; p < 0.001), LDL cholesterol (-21% versus -3%; p = 0.026), and triglycerides (-41% versus +18%; p = 0.001) significantly decreased during RAL therapy compared to the control. Furthermore, a rel...Continue Reading

Associated Clinical Trials

References

May 3, 2006·The Journal of Infectious Diseases·Jessica R GrubbMark T Gladwin
Apr 27, 2007·The New England Journal of Medicine·UNKNOWN DAD Study GroupJens D Lundgren
Jul 19, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael P DubéKieren J Mather
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kenneth A LichtensteinUNKNOWN HIV Outpatient Study (HOPS) Investigators
Jul 6, 2010·Atherosclerosis·Remy H H BemelmansFrank L J Visseren
Jan 12, 2011·The Journal of Experimental Medicine·Daniel O GriffinThomas L Rothstein
Mar 30, 2012·European Journal of Preventive Cardiology·Eli-Anne SkaugOyvind Ellingsen
Apr 24, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerUNKNOWN AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis
Oct 9, 2012·International Journal of Cardiology·Rouyanne T RasPeter L Zock
Nov 2, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Dimitrios TsiantoulasChristoph J Binder
Apr 24, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Theodoros KelesidisGrace A McComsey

❮ Previous
Next ❯

Citations

Nov 18, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Jesús TroyaLuis Álvarez-Sala Walther

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.